Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
April 25, 2025
Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology │ Leadership │ Article
If you are a journalist or member of the media looking for Takeda Oncology resources, visit the media materials section of our newsroom.
For other Takeda news releases, please visit the Takeda.com Newsroom.
For media inquiries or reporter requests for more information, contact Oncology Communications via [email protected]. If you generally would like to contact us, please visit Contact Us.